A federal initiative to ensure that the United States can respond to biological threats at home will be put to the test in response to the Ebola outbreak in West Africa.
A Texas site is preparing to manufacture the experimental Ebola drug ZMapp, says Robin Robinson, director of the Biomedical Advanced Research and Development Authority (BARDA), a division within the U.S. Department of Health and Human Services. Robinson adds that Novartis’s (NYSE: NVS) vaccine facility in North Carolina is a possible second site to make the drug. Those sites were developed previously in partnership with a U.S. government effort to establish response centers capable of manufacturing drugs and vaccines in an emergency.
Help employers find you! Check out all the jobs and post your resume.
